Terns Pharmaceuticals Inc (TERN)
6.01
-1.01
(-14.39%)
USD |
NASDAQ |
May 31, 16:00
6.04
+0.03
(+0.50%)
Pre-Market: 20:00
Terns Pharmaceuticals SG&A Expense (Annual): 39.06M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 39.06M |
| December 31, 2022 | 22.41M |
| December 31, 2021 | 19.55M |
| Date | Value |
|---|---|
| December 31, 2020 | 8.996M |
| December 31, 2019 | 8.663M |
| December 31, 2018 | 3.901M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
8.663M
Minimum
2019
39.06M
Maximum
2023
19.74M
Average
19.55M
Median
2021
SG&A Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 37.02M |
| Eli Lilly and Co | 6.941B |
| Pfizer Inc | 14.77B |
| Amgen Inc | 6.179B |
| Madrigal Pharmaceuticals Inc | 108.15M |